Compass Therapeutics

CMPX

Market cap $1B

Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.

The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway extends into 2028, supporting continued clinical progress and mitigating near-term financing risk.

Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), a previously reported third response has now been confirmed in a patient with Hodgkin Lymphoma (HL).

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. “We are thrilled to welcome Arjun and Cyndi to the Compass team.

Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026.

The consensus price target hints at a 134.1% upside potential for Compass Therapeutics, Inc. (CMPX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.